Artrya (ASX: AYA) shares could be worth considering if you are searching for exposure to artificial intelligence (AI).
That's the view of analysts at Bell Potter, who are bullish on the ASX AI stock.
What is the broker saying about this ASX AI stock?
Firstly, in case you are not familiar with Artrya, it is a medical technology company using AI-powered image-analysis software to improve the detection and management of coronary artery disease (CAD).
Bell Potter notes that CAD is driven by soft plaque that builds up silently in the arteries and ruptures without warning, causing a fatal heart attack. Traditional cardiac diagnostics often fail to detect this hidden risk, and in over 50% of the population, the first sign of the disease is sudden death.
This condition affects around 126 million people globally each year, causing around 9 million deaths, with the vast majority of patients experiencing no warning signs.
This gives the ASX AI stock a very large market opportunity.
A recent note reveals that Bell Potter has been pleased with Artrya's progress in 2026 and is optimistic on its outlook. It said:
Following completion of onboarding Tanner Health's five hospitals, scanning has now commenced, with monthly scan volumes increasing through the quarter. Reimbursement and back-office processes are in the final stages of completion. Both NGHS and Cone Health are working through onboarding processes and expect to be ready for scanning patients for anatomy and plaque by the beginning of FY27.
The Blood Flow (FFRCT / SCF) module is being prepared for submission to the FDA under the 510(k) submission, with a 1H27 targeted commercial rollout. Training materials and reimbursement administration are being addressed in anticipation of the commercial rollout to foundational customers. Contracting and ethics approval submissions are in progress at all six SAPPHIRE study partners, with an initial Principal Investigator meeting schedule for July 2026.
Should you invest?
According to the note, Bell Potter has a buy rating and $6.10 price target on the ASX AI stock.
Based on its current share price of $4.87, this implies potential upside of 25% for investors over the next 12 months.
Commenting on its buy thesis, the broker said:
AYA's first customer has now progressed to scanning patients and the other two foundational customers should be ready for the beginning of FY27. AYA is progressing as expected, and the key catalyst now is disclosure of quarterly scan volumes.
Verification of scan volumes is necessary to prove out our model assumptions and validate the investment thesis of a fundamental shift in the diagnostic method of CAD. AYA's share price has increased c.6x since this time last year, implying a successful rollout and high degree of growth. Yet, given the nature of the value proposition, proof of commercial execution is likely to keep valuation metrics elevated.
The post Which exciting ASX AI stock is a buy according to a leading broker? appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026